Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.
about
The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemiaCellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell linesAcquired pure red cell aplasia: updated review of treatmentHighlights on endoglin (CD105): from basic findings towards clinical applications in human cancerEnhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice.CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's LymphomasReal time assays for quantifying cytotoxicity with single cell resolutionStructural basis for recognition of CD20 by therapeutic antibody RituximabTheranostic applications of antibodies in oncology.Rituximab in autoimmune diseasesIgE immunotherapy against cancerBone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistanceAccelerated identification of proteins by mass spectrometry by employing covalent pre-gel staining with Uniblue AManagement of allosensitized cardiac transplant candidatesAntigenic modulation and rituximab resistance.Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges.Repeated courses of rituximab in chronic ITP: Three different regimens.Successful treatment with thrombopoietin receptor agonist in avoiding splenectomy for patients with chronic refractory immune thrombocytopeniaA New Kid on the Block: IL-10+ Regulatory B Cells and a Possible Role In Psoriasis.Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood.Genetic polymorphisms of STAT3 correlated with prognosis in diffuse large B-cell lymphoma patients treated with rituximab.Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice.Rituximab Treatment for Idiopathic Hypertrophic Pachymeningitis.Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab.Preemptive CD20+ B cell depletion attenuates cardiac allograft vasculopathy in cyclosporine-treated monkeys.Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma.Prokaryotic expression of MLAA-34 and generation of a novel human ScFv against MLAA-34 by phage display technologySimultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.An update on the use of biologic therapies in the management of uveitis in Behçet's disease: a comprehensive review.Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses.Induction of apoptosis by cross-linking antibodies bound to human B-lymphoma cells: expression of Annexin V binding sites on the antibody capImmunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease.Non-infectious pulmonary toxicity of rituximab: a systematic review.Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphomaTreatment of autoimmune hepatitis: a review of current and evolving therapies.Vaccines and immunotherapeutics for the treatment of malignant diseaseHighly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse.Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.Liposomes modified by carbohydrate ligands can target B cells for the treatment of B-cell lymphomas.The spectrum of use of rituximab in chronic lymphocytic leukemia
P2860
Q24617708-E0823BE2-408A-4927-A8C3-F47845010B9EQ24650717-EACAFB89-E953-4FD5-84B3-12B42950D57AQ24652253-33EBB5D4-7BA7-442B-9F05-2EC1B8805859Q24798737-0EB72666-8BE0-4A22-A53A-4F53C376C205Q24813078-4856879F-F03E-423E-B253-BBFFCCD9CB2FQ26749139-1CF33DD3-D6CE-466D-BFCD-9A362E4564B3Q27313805-37729B71-92CE-4DAE-9935-5081FE3FA399Q27644280-1583C340-455B-4C33-8FE3-80A8D48635C2Q27693293-348551C7-E4FC-4F84-BF71-6770AF715CA0Q28076091-F083D011-23A0-451B-9761-DD0AABDFB102Q28081223-1F6E2152-8895-4BA2-ACF5-DED192CE3C6CQ28243054-F7A50313-51E8-475F-897C-94C4DAC26DF3Q28480945-988026D1-F402-425F-9AB6-2F0282E40BA6Q28749508-DFEA90DD-FCE9-40E3-B0B5-972B87BFDD2DQ30432874-F28F378F-7274-463C-8FAF-636C75489D6DQ33224048-36A22728-D610-4EB6-8F27-9ED7E74042B7Q33386117-2C8F4D78-C0AC-4E7B-93ED-8BEFE67DDA61Q33399821-A8890B45-198F-42B1-B8EA-027338E6FD2CQ33403761-64785FE2-1D4F-4993-8FA0-9867F58DE064Q33410392-ED35B8EE-0D25-4962-A647-0FCF6E2F2D4EQ33556514-4BE6BB38-E451-48E7-B86D-C2A221D8AF5AQ33560416-F15E6E1A-0773-409A-9346-1D9F2C42A5DCQ33567252-6FFF562F-980E-4211-BA6B-80C9B5863D9EQ33691650-116F24AD-CF08-4D5B-B8AF-A92F518C2A95Q33755443-316F1F29-13C6-48F9-B805-D7B03FEC2CD2Q33788697-73E4DFC8-1F26-4FB0-BDAB-82842909FC9BQ33889089-6708FF0B-39E3-4A27-BE74-F8E31A02AC86Q33889191-AB19F733-74D4-4418-A56B-9AFAB7600CE1Q33910781-0A4DBDCA-B103-4310-A7F8-50C37F16FDFEQ33971785-28DFD2F2-F8C1-4FDD-ABCD-C6202D83020AQ33985565-9B4E32C4-FEEC-41DA-9CD4-7BEAFEEDDF8DQ34085036-6748C613-6AC3-419F-BC34-D0529A29F0A9Q34096300-1CC124D9-357D-4EF4-8921-43E6044B6142Q34144940-4F011F95-136E-46FA-9C8F-E04AD55F6D14Q34149523-EB089E2C-652B-4D68-B00D-9E8C1CEF50E2Q34170074-BE012E11-AA2B-40A9-8D70-AC86943A2A59Q34223872-0E33DE48-EFA1-4C3A-98F4-CB6B8FA0F5E4Q34310912-50C48B5C-A048-4417-9F80-32B42EFC33AEQ34470480-432B4B4A-F697-45F7-863E-6ABC18B0C0E2Q34510030-B1D78968-F917-4698-9DA1-4A265DFA5BE6
P2860
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.
@ast
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.
@en
type
label
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.
@ast
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.
@en
prefLabel
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.
@ast
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.
@en
P2860
P356
P1433
P1476
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.
@en
P2093
Mitchell R Smith
P2860
P2888
P304
P356
10.1038/SJ.ONC.1206939
P407
P577
2003-10-01T00:00:00Z